Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study
- 18 August 2015
- journal article
- research article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 20 (1) , 103-108
Abstract
Aim The primary aim of this study was to explore the safety profile of biologic treatments in Behçet's disease (BD), based on their mechanism of action; the secondary aim was to study any potential variation in terms of retention rate according to each single drug. Method We studied a total of 85 treatment regimens with biologic agents from 64 patients. The total follow‐up was calculated as 8640 patient‐years (anti‐tumor necrosis factor [TNF]‐alpha 7.020, anti‐interleukin [IL]‐beta 1.368). Cumulative rates of drug retention were studied using the Kaplan–Meier plot and covariates in the regression model included the mechanism of action of the biologic agent, other concomitant therapies, disease duration, sex, age at start of drug therapy; for each confounding factor hazard ratios (HR) were calculated. Results The most frequently prescribed biologic treatments were anti‐TNF‐alpha agents (79%), while anti‐IL1‐beta was used in the remaining regimens. Concomitant disease‐modifying antirheumatic drugs were prescribed in 36% of patients, mainly cyclosporine and methotrexate, while in 35/85 regimens low‐dose glucocorticoids were associated. During the follow‐up, in all but one regimen the safety profile was free of any adverse events or serious adverse events; we observed only one case of endocarditis, reported during the 10th month of etanercept. Conclusion Data from a large multicenter cohort suggest that anti‐TNF‐alpha and anti‐IL1‐beta agents are characterized by an excellent safety profile in BD.Keywords
This publication has 25 references indexed in Scilit:
- Biotherapies in Behçet's diseaseAutoimmunity Reviews, 2014
- Biological Treatments in Behçet’s Disease: Beyond Anti-TNF TherapyMediators of Inflammation, 2014
- Behçet Syndrome Manifestations and Activity in the United States versus Turkey — A Cross-sectional Cohort ComparisonThe Journal of Rheumatology, 2014
- Criteria for Behçet's disease with reflections on all disease criteriaJournal of Autoimmunity, 2014
- The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF‐αEuropean Journal of Immunology, 2013
- Rate of serious infections in Behçet’s disease patients receiving biologic therapies: a prospective observational studyClinical Rheumatology, 2013
- Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet's disease: an international cohort study of 110 patients. One-year follow-up dataRheumatology, 2010
- Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet diseaseAnnals of the Rheumatic Diseases, 2009
- Safety and Efficacy of Etanercept in Children with Juvenile-Onset Behcet's DiseaseInternational Journal of Immunopathology and Pharmacology, 2009
- Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: A seventeen‐year population‐based studyArthritis Care & Research, 2007